Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed/refractory B-ALL after CD19-CAR T-Cell therapy
Testing for specific genetic changes before CAR-T therapy helps doctors predict who needs extra treatment to prevent relapse.
This study identifies TP53 alterations as a strong adverse prognostic factor in pediatric/YA B-ALL treated with CAR-T therapy, with dramatically worse EFS and OS. The findings support pre-CAR-T TP53 screening to guide risk-adapted consolidation strategies.
What the study was
- Study design
- Retrospective single-center cohort
- Population
- Pediatric/young adult r/r B-ALL patients treated with Tisagenlecleucel (N=69, 49 with samples)
- Sample size
- 69
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Bone Marrow Transplantation
Why it surfaced
Clinically actionable finding on TP53 as prognostic biomarker in CAR-T for B-ALL. Single-center retrospective limits design score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.